EUVIMEDEUVIMED entdecken
Open Access

Glucagon‐Like Peptide‐1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis–Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts

Rebecca H Haberman iD, Alexandra L Rice, Kyra Chen, Uma Scher, Sydney Thib, Jose U Scher iD, Lihi Eder iD

Arthritis & Rheumatology · 2026-11 · 78 (11) · 2274-2279

DOI: 10.1002/art.70170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 27.04.2026. Verfasst von Rebecca H Haberman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Rheumatology, New York University (NYU) Grossman School of Medicine, New York, New York. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Psoriasis Foundation, The Beatrice Snyder Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Obesity is highly prevalent in psoriatic arthritis (PsA) and is associated with worse disease outcomes. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly being used for weight loss and diabetes, but their impact on PsA outcomes remains unclear. We aimed to characterize patients with PsA initiating GLP‐1RAs and assess longitudinal changes in weight, PsA activity, and cardiometabolic parameters.

Methods

We conducted a retrospective analysis of patients with PsA who initiated GLP‐1RAs. PsA disease activity data and cardiometabolic parameters from clinical visits within one year before and after GLP‐1RA initiation, along with demographics and comorbidities, were collected.

Results

Forty‐eight patients with a median body mass index of 34.9 were included. Significant weight loss was observed posttreatment (−6.43 kg, 95% confidence interval [CI] −9.5 to −2.0; P < 0.0001), with 60% losing ≥5% of their baseline bodyweight. C‐reactive protein levels (−1.1 mg/L; P = 0.002), pain scores (−1.0; P = 0.01), and triglyceride levels (−0.35 mmol/L; P = 0.02) decreased significantly. Each 1% reduction in body weight was associated with significant improvements in the Disease Activity in Psoriatic Arthritis score (β = −0.49, 95% CI −0.94 to −0.03), tender joint count (β = −0.18, 95% CI −0.32 to −0.05), EuroQol 5‐domain (β = 0.0016, 95% CI 0.008–0.023), low‐density lipoprotein cholesterol levels (β = −0.05, 95% CI −0.10 to −0.003), and systolic blood pressure (β = −0.67, 95% CI −1.18 to −0.15).

Conclusion

In this real‐world study, GLP‐1RA therapy in PsA was associated with clinically meaningful weight loss and improvements in systemic inflammation, pain, and cardiometabolic markers. Improvements in psoriatic outcomes were proportional to the degree of weight loss. These findings warrant further investigation in prospective controlled studies to evaluate the role of GLP‐1RAs in PsA management and comorbidities. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticGlucagon-Like Peptide-1 Receptor AgonistsObesityHumansRetrospective StudiesFemaleMaleMiddle AgedWeight LossC-Reactive ProteinTreatment OutcomeAdultBody Mass IndexTriglycerides

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsC-Reactive ProteinTriglycerides

Autor:innen und Institutionen

  • Department of Medicine, Division of Rheumatology, New York University (NYU) Grossman School of Medicine, New York, New York.
  • Department of Medicine, Division of Rheumatology, University of Toronto and Women's College Hospital, Toronto, Ontario, Canada.
  • NYU Colton Center for Autoimmunity, NYU Langone Health, New York, New York.

ORCID-Profile: Rebecca H Haberman, Jose U Scher, Lihi Eder

Förderung

  • NIAMS NIH HHS
  • National Psoriasis Foundation
  • The Beatrice Snyder Foundation
  • The Riley Family Foundation
  • NYU Colton Center for Autoimmunity
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Haberman, R. H., Rice, A. L., Chen, K., Scher, U., Thib, S., Scher, J. U., & Eder, L. (2026). Glucagon‐Like Peptide‐1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis–Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts. Arthritis & Rheumatology, 78(11), 2274-2279. https://doi.org/10.1002/art.70170

Vancouver

Haberman RH, Rice AL, Chen K, Scher U, Thib S, Scher JU, et al. Glucagon‐Like Peptide‐1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis–Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts. Arthritis & Rheumatology. 2026;78(11):2274-2279. doi:10.1002/art.70170

BibTeX
@article{Haberman2026,
  author = {Haberman, Rebecca H and Rice, Alexandra L and Chen, Kyra and Scher, Uma and Thib, Sydney and Scher, Jose U and Eder, Lihi},
  title = {Glucagon‐Like Peptide‐1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis–Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  volume = {78},
  number = {11},
  pages = {2274--2279},
  doi = {10.1002/art.70170}
}
Kostenlos starten →